tiprankstipranks
Advertisement
Advertisement

KSPHF Stock Latest News

Kissei Pharmaceutical Reports Progress on Share Buyback Program
Company AnnouncementsKissei Pharmaceutical Reports Progress on Share Buyback Program
4d ago
Kissei Pharmaceutical Finalizes Adjusted Treasury Share Disposal for Employee Stock Plan
PremiumCompany Announcements
Kissei Pharmaceutical Finalizes Adjusted Treasury Share Disposal for Employee Stock Plan
28d ago
Kissei Pharmaceutical Reports No Treasury Share Purchases in July Under Ongoing Buyback Plan
PremiumCompany Announcements
Kissei Pharmaceutical Reports No Treasury Share Purchases in July Under Ongoing Buyback Plan
1M ago
Kissei Pharmaceutical Cuts Earnings Forecasts on Weak TAVNEOS Sales
PremiumCompany Announcements
Kissei Pharmaceutical Cuts Earnings Forecasts on Weak TAVNEOS Sales
1M ago
Kissei Pharmaceutical Highlights Q1 FY2026 Results and R&D Pipeline Focus
PremiumCompany Announcements
Kissei Pharmaceutical Highlights Q1 FY2026 Results and R&D Pipeline Focus
1M ago
Kissei Pharmaceutical Posts Mixed Q1 Results, Lifts Dividends but Cuts FY2027 Outlook
PremiumCompany AnnouncementsKissei Pharmaceutical Posts Mixed Q1 Results, Lifts Dividends but Cuts FY2027 Outlook
1M ago
Kissei Pharmaceutical Co (KSPHF) Q1 Earnings Cheat Sheet
Premium
Pre-Earnings
Kissei Pharmaceutical Co (KSPHF) Q1 Earnings Cheat Sheet
1M ago
Kissei Pharmaceutical Completes Treasury Share Disposal for Executive Restricted Stock
Premium
Company Announcements
Kissei Pharmaceutical Completes Treasury Share Disposal for Executive Restricted Stock
2M ago
Kissei Pharmaceutical Reports No Share Buybacks Yet Under 2026 Repurchase Program
PremiumCompany Announcements
Kissei Pharmaceutical Reports No Share Buybacks Yet Under 2026 Repurchase Program
2M ago
Kissei Faces EU Setback as EMA Backs Revocation of TAVNEOS Authorization
PremiumCompany Announcements
Kissei Faces EU Setback as EMA Backs Revocation of TAVNEOS Authorization
2M ago
Kissei Pharmaceutical Grants Restricted Stock to Board Members and Officers
PremiumCompany Announcements
Kissei Pharmaceutical Grants Restricted Stock to Board Members and Officers
3M ago
Kissei Pharmaceutical Sets Share Buyback Framework but Executes No Purchases in May
PremiumCompany Announcements
Kissei Pharmaceutical Sets Share Buyback Framework but Executes No Purchases in May
3M ago
Kissei Files Japan NDA for IDH1-Targeting AML Drug Olutasidenib
PremiumCompany AnnouncementsKissei Files Japan NDA for IDH1-Targeting AML Drug Olutasidenib
3M ago
Kissei Tightens Safety Warnings on TAVNEOS After Serious Liver Risk Cases
Premium
Company Announcements
Kissei Tightens Safety Warnings on TAVNEOS After Serious Liver Risk Cases
4M ago
Kissei Restricts TAVNEOS Use in Japan After Global Safety and Data Concerns
Premium
Company Announcements
Kissei Restricts TAVNEOS Use in Japan After Global Safety and Data Concerns
4M ago
Kissei Pharmaceutical Posts Record Sales as R&D Investment and Overseas Growth Intensify
PremiumCompany Announcements
Kissei Pharmaceutical Posts Record Sales as R&D Investment and Overseas Growth Intensify
4M ago
Kissei Pharmaceutical Launches ¥6 Billion Share Buyback and Cancellation Plan
PremiumCompany Announcements
Kissei Pharmaceutical Launches ¥6 Billion Share Buyback and Cancellation Plan
4M ago
Kissei Pharmaceutical Details FY2026 Results and R&D Pipeline in Supplementary Report
PremiumCompany Announcements
Kissei Pharmaceutical Details FY2026 Results and R&D Pipeline in Supplementary Report
4M ago
Kissei Pharmaceutical Swings to Operating Loss but Lifts Payouts and Eyes Profit Recovery
PremiumCompany Announcements
Kissei Pharmaceutical Swings to Operating Loss but Lifts Payouts and Eyes Profit Recovery
4M ago
KSPHF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsKSPHF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
4M ago
Kissei sublicenses AML drug olutasidenib to Orient EuroPharma in Taiwan
Premium
Company Announcements
Kissei sublicenses AML drug olutasidenib to Orient EuroPharma in Taiwan
4M ago
Kissei Pharmaceutical Names Research Chief Keiji Miyazawa as New President and COO
Premium
Company Announcements
Kissei Pharmaceutical Names Research Chief Keiji Miyazawa as New President and COO
5M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >